Who are Subject's habitual PGA monotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/subject-s-habitual-pga-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Subject's habitual PGA monotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subject's habitual PGA monotherapy (Subject's habitual PGA monotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog (PGA). Area: Ophthalmology.

marketed Prostaglandin analog (PGA) Prostaglandin F (FP) receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Subject's habitual PGA monotherapy (Subject's habitual PGA monotherapy) — Alcon, a Novartis Company. PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Subject's habitual PGA monotherapy TARGET	Subject's habitual PGA monotherapy	Alcon, a Novartis Company	marketed	Prostaglandin analog (PGA)	Prostaglandin F (FP) receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog (PGA) class)

Alcon, a Novartis Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Subject's habitual PGA monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/subject-s-habitual-pga-monotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab